- Home
- Equipment
- north america
- antigen targeted
Refine by
Antigen Targeted Equipment Supplied In North America
41 equipment items found
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Anti-ROBO1 is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells.MW: 145.5 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanized monoclonal antibody which targets Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with immunostimulating and antineoplastic activities. MW : 146.48 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Labetuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanised monoclonal antibody targeting carcinoembryonic antigen (CEA). It inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. MW :145.36 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 ...
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
NK cells play a major role in the anti-tumor efficacy of certain tumor-antigen targeting antibodies. NK cells express CD16, an activating receptor that binds to the Fc portion of IgG antibodies. Once activated through CD16, NK cells are able to destroy antibody-coated target cells and secrete cytokines, such as interferon gamma, to recruit and ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
Our exclusive iSORT (Isolation of Optimal Reverse Immunology Generated TCR) platform is able to isolate TCRs against unique selected tumor-associated intracellular and extracellular antigens and neoantigens in the context of an HLA molecule, allowing us to focus on specific cancers and patient populations based on their genetic makeups. Using this technology, we are able to ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
SynCon uses a proprietary computer algorithm that has been designed to identify and optimize the DNA sequence of the target antigen, whether it is a virus or a tumor. Once this sequence has been determined, the DNA is synthesized or reorganized, and manufacturing can ...
by:DxDiscovery, Inc. based inReno, NEVADA (USA)
An essential aspect of immunoassay development is the identification of target antigens that are shed or secreted during infection that can be used as targets for diagnosis. In an attempt to identify circulating bacterial and fungal antigens that possess diagnostic potential, we developed a platform technology called “In ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA smart devices. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T ...
Manufactured by:Blue Earth Diagnostics based inOxford, UNITED KINGDOM
Therapeutic nuclear medicine, also known as theranostics, combines tumour targeting with a therapeutic dose of radiation. Tumour targeting allows radiopharmaceuticals to selectively target cells associated with disease due to the affinity between the drug and certain receptors expressed by the relevant cells. The targeting ...
by:Kephera Diagnostics, LLC based inFramingham, MASSACHUSETTS (USA)
Our proprietary assay technology is based on principles of particle interaction combined with a simple device, which together enable rapid detection of specific antibodies or antigens associated with the target pathogen. The broadly enabling technology is applicable to a wide range of disease targets and applications. Kephera’s expertise ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
These same technologies are now the basis for the Company’s expansion into therapeutic applications for the treatment of cancer and infectious disease. Qualigen’s Selective Target Antigen Removal System (STARS), is an investigational therapeutic device product currently under development and evaluation that will utilize core expertise in advanced ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of cancer, including 40% ...
Manufactured by:NeoClone based inMadison, WISCONSIN (USA)
NeoClone is a world-class custom antibody development company, having discovered hundreds of antibodies for our clients. But there are very difficult targets out there that hybridoma technology alone can't solve. So we added antibody phage display capabilities to help us develop the diverse and specific antibody repertoire to difficult targets that you need. Our team now has over 15 years of ...
Manufactured by:Immudex ApS based inVirum, DENMARK
SARS-CoV-2-specific CD4+ and CD8+ T cells are present for at least a year after infection with COVID-19. Functional T cells targeting multiple antigens of SARS-CoV-2 are detected in mild and severe COVID-19, as well as asymptomatic ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune checkpoint target. 4-1BB targeting antibodies being developed by multinational companies have exhibited dose-dependent liver toxicity in clinical trials, ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
Manufactured by:Twist Bioscience based inSouth San Francisco, CALIFORNIA (USA)
The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic ...